Recruiting Melanoma Studies in Aurora
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab al...
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive eit...
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants w...
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may hav...
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during ...
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneo...
About Melanoma Clinical Trials in Aurora
Melanoma is the most serious type of skin cancer, developing from the pigment-producing cells known as melanocytes. While less common than other skin cancers, melanoma is more likely to spread. Immunotherapy and targeted therapy have revolutionized melanoma treatment.
There are currently 7 melanoma clinical trials recruiting participants in Aurora, ILLINOIS. These studies are seeking a combined 2,387 participants. Research is being sponsored by Immunocore Ltd, Iovance Biotherapeutics, Inc., IDEAYA Biosciences and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Melanoma Clinical Trials in Aurora — FAQ
Are there melanoma clinical trials in Aurora?
Yes, there are 7 melanoma clinical trials currently recruiting in Aurora, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Aurora?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.
Are clinical trials in Aurora free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.
What melanoma treatments are being tested?
The 7 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for melanoma.
Data updated March 2, 2026 from ClinicalTrials.gov